Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335115 | PMC |
| http://dx.doi.org/10.3324/haematol.2021.280312 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activation of PD-1/PD-L1 immune checkpoint by Zika virus.
PLoS Pathog
September 2025
School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
Zika virus (ZIKV) has emerged as a rising concern in global health in recent years. The role of PD-1/PD-L1 immune checkpoint in acute ZIKV infection remains to be understood. In this study we demonstrated the activation of PD-1/PD-L1 immune checkpoint by ZIKV.
View Article and Find Full Text PDFSLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8 T cells to immune checkpoint blockade.
Front Immunol
September 2025
Department of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Tumors frequently evade immune destruction by impairing cytotoxic CD8 T-cell responses, highlighting the need for strategies that restore T-cell functionality. Here, we identify SLAMF7 (CD319) as a key enhancer of human CD8 T-cell responses against tumors. SLAMF7 expression is induced by pro-inflammatory signals such as IL-12 and CD28 co-stimulation.
View Article and Find Full Text PDFONECUT1 activates PSAT1 to facilitate PD-L1 expression and mediate immune evasion of lung squamous cell carcinoma.
Tissue Cell
August 2025
Department of Thoracic Surgery, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530016, China. Electronic address:
Background: PD-1/PD-L1, a classic immune checkpoint commonly employed in targeted therapy, has proven to yield only limited benefits for patients with lung squamous cell carcinoma (LUSC). Unraveling the intrinsic mechanisms underlying the progression of LUSC serves as the foundation for discovering more effective treatment strategies.
Methods: A study was conducted on the differential expression of PSAT1 and ONECUT1 in LUSC based on data from the TCGA database.
Altered B cell subset distribution and expression of PD-1 in preeclampsia patients.
Placenta
August 2025
Medical Microbiology and Immunology Department, Faculty of Medicine, Assiut University, Assiut, Egypt; Department of Basic Medical Sciences, Faculty of Oral & Dental Medicine, Badr University in Assiut (BUA), Egypt. Electronic address:
Background And Aim: The role of the programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) axis in the pathogenesis of preeclampsia (PE) is currently a subject of research interest. This work aimed to characterize different B cell subsets and their PD-1 expression levels in 54 PE patients compared with 21 age-matched women having normal, uncomplicated pregnancies of comparable gestational age. Also, to evaluate the possibility of a relation between the levels of these subsets with disease severity and the antihypertensive therapy.
View Article and Find Full Text PDFImmune checkpoints in immune response to glioma: two sides of the same coin.
Front Immunol
September 2025
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Gliomas are aggressive brain tumors of glial origin accounting for about 80% of the central nervous system (CNS) malignancies. Glioma cells are known to form a highly immunosuppressive tumor microenvironment (TME) capable of inhibiting T cell activation and protecting tumors from elimination by the immune system. One of the predominant immune inhibitory mechanisms in the TME are immune checkpoints: a complex system of membrane-bound ligands on tumor and immune cells that interact with surface receptors on T lymphocytes and affect their activation and cytotoxicity.
View Article and Find Full Text PDF